310 related articles for article (PubMed ID: 21437870)
1. Calcium signaling in systemic lupus erythematosus T cells: a treatment target.
Kyttaris VC; Zhang Z; Kampagianni O; Tsokos GC
Arthritis Rheum; 2011 Jul; 63(7):2058-66. PubMed ID: 21437870
[TBL] [Abstract][Full Text] [Related]
2. Disease Stage-Specific Pathogenicity of CD138 (Syndecan 1)-Expressing T Cells in Systemic Lupus Erythematosus.
Liu L; Takeda K; Akkoyunlu M
Front Immunol; 2020; 11():1569. PubMed ID: 32849532
[TBL] [Abstract][Full Text] [Related]
3. A benzenediamine derivative fc-99 attenuates lupus-like syndrome in MRL/lpr mice related to suppression of pDC activation.
Ji J; Fan H; Li F; Li X; Dong G; Gong W; Song Y; Liu F; Hua C; Tan R; Dou H; Hou Y
Immunol Lett; 2015 Dec; 168(2):355-65. PubMed ID: 26545567
[TBL] [Abstract][Full Text] [Related]
4. Interleukin-9 Is Associated with Elevated Anti-Double-Stranded DNA Antibodies in Lupus-Prone Mice.
Yang J; Li Q; Yang X; Li M
Mol Med; 2015 Apr; 21(1):364-70. PubMed ID: 25902303
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of EZH2 Ameliorates Lupus-Like Disease in MRL/lpr Mice.
Rohraff DM; He Y; Farkash EA; Schonfeld M; Tsou PS; Sawalha AH
Arthritis Rheumatol; 2019 Oct; 71(10):1681-1690. PubMed ID: 31106974
[TBL] [Abstract][Full Text] [Related]
6. Imatinib and M351-0056 enhance the function of VISTA and ameliorate the development of SLE via IFN-I and noncanonical NF-κB pathway.
Yang L; Zhang T; Wang P; Chen W; Liu W; He X; Zhang Y; Jin S; Luo Z; Zhang Z; Wang X; Liu J
Cell Biol Toxicol; 2023 Dec; 39(6):3287-3304. PubMed ID: 37804401
[TBL] [Abstract][Full Text] [Related]
7. Reducing FLI1 levels in the MRL/lpr lupus mouse model impacts T cell function by modulating glycosphingolipid metabolism.
Richard EM; Thiyagarajan T; Bunni MA; Basher F; Roddy PO; Siskind LJ; Nietert PJ; Nowling TK
PLoS One; 2013; 8(9):e75175. PubMed ID: 24040398
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of microRNA-448 suppresses CD4
Zhang J; Guo Y; Sun Y; Chang L; Wang X
Biochem Biophys Res Commun; 2022 Mar; 596():88-96. PubMed ID: 35121374
[TBL] [Abstract][Full Text] [Related]
9. Effects of FTY720 in MRL-lpr/lpr mice: therapeutic potential in systemic lupus erythematosus.
Okazaki H; Hirata D; Kamimura T; Sato H; Iwamoto M; Yoshio T; Masuyama J; Fujimura A; Kobayashi E; Kano S; Minota S
J Rheumatol; 2002 Apr; 29(4):707-16. PubMed ID: 11950011
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of glutaminolysis ameliorates lupus by regulating T and B cell subsets and downregulating the mTOR/P70S6K/4EBP1 and NLRP3/caspase-1/IL-1β pathways in MRL/lpr mice.
Zhang X; Wang G; Bi Y; Jiang Z; Wang X
Int Immunopharmacol; 2022 Nov; 112():109133. PubMed ID: 36113317
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic effects of artesunate on lupus-prone MRL/lpr mice are dependent on T follicular helper cell differentiation and activation of JAK2-STAT3 signaling pathway.
Dang WZ; Li H; Jiang B; Nandakumar KS; Liu KF; Liu LX; Yu XC; Tan HJ; Zhou C
Phytomedicine; 2019 Sep; 62():152965. PubMed ID: 31129432
[TBL] [Abstract][Full Text] [Related]
12. Function of the Th17/interleukin-17A immune response in murine lupus nephritis.
Schmidt T; Paust HJ; Krebs CF; Turner JE; Kaffke A; Bennstein SB; Koyro T; Peters A; Velden J; Hünemörder S; Haag F; Steinmetz OM; Mittrücker HW; Stahl RA; Panzer U
Arthritis Rheumatol; 2015 Feb; 67(2):475-87. PubMed ID: 25385550
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin reverses the senescent phenotype and improves immunoregulation of mesenchymal stem cells from MRL/lpr mice and systemic lupus erythematosus patients through inhibition of the mTOR signaling pathway.
Gu Z; Tan W; Ji J; Feng G; Meng Y; Da Z; Guo G; Xia Y; Zhu X; Shi G; Cheng C
Aging (Albany NY); 2016 May; 8(5):1102-14. PubMed ID: 27048648
[TBL] [Abstract][Full Text] [Related]
14. Antagonizing miR-7 suppresses B cell hyperresponsiveness and inhibits lupus development.
Wang M; Chen H; Qiu J; Yang HX; Zhang CY; Fei YY; Zhao LD; Zhou JX; Wang L; Wu QJ; Zhou YZ; Zhang W; Zhang FC; Zhang X; Lipsky PE
J Autoimmun; 2020 May; 109():102440. PubMed ID: 32201226
[TBL] [Abstract][Full Text] [Related]
15. Vascular Inflammation and Dysfunction in Lupus-Prone Mice-IL-6 as Mediator of Disease Initiation.
Marczynski P; Meineck M; Xia N; Li H; Kraus D; Roth W; Möckel T; Boedecker S; Schwarting A; Weinmann-Menke J
Int J Mol Sci; 2021 Feb; 22(5):. PubMed ID: 33669022
[TBL] [Abstract][Full Text] [Related]
16. Cryptotanshinone ameliorates the pathogenesis of systemic lupus erythematosus by blocking T cell proliferation.
Du Y; Du L; He Z; Zhou J; Wen C; Zhang Y
Int Immunopharmacol; 2019 Sep; 74():105677. PubMed ID: 31177018
[TBL] [Abstract][Full Text] [Related]
17. Impaired dynamic X-chromosome inactivation maintenance in T cells is a feature of spontaneous murine SLE that is exacerbated in female-biased models.
Jiwrajka N; Toothacre NE; Beethem ZT; Sting S; Forsyth KS; Dubin AH; Driscoll A; Stohl W; Anguera MC
J Autoimmun; 2023 Sep; 139():103084. PubMed ID: 37399593
[TBL] [Abstract][Full Text] [Related]
18. Mitochondrial Dysfunction in the Liver and Antiphospholipid Antibody Production Precede Disease Onset and Respond to Rapamycin in Lupus-Prone Mice.
Oaks Z; Winans T; Caza T; Fernandez D; Liu Y; Landas SK; Banki K; Perl A
Arthritis Rheumatol; 2016 Nov; 68(11):2728-2739. PubMed ID: 27332042
[TBL] [Abstract][Full Text] [Related]
19. Overexpression of FcγRIIB regulates downstream protein phosphorylation and suppresses B cell activation to ameliorate systemic lupus erythematosus.
Sheng L; Cao X; Chi S; Wu J; Xing H; Liu H; Yang Z
Int J Mol Med; 2020 Oct; 46(4):1409-1422. PubMed ID: 32945349
[TBL] [Abstract][Full Text] [Related]
20. IL-23 Limits the Production of IL-2 and Promotes Autoimmunity in Lupus.
Dai H; He F; Tsokos GC; Kyttaris VC
J Immunol; 2017 Aug; 199(3):903-910. PubMed ID: 28646040
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
